• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SRNE

    Sorrento Therapeutics Inc.

    Subscribe to $SRNE
    $SRNE
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

    IPO Year:

    Exchange: NASDAQ

    Website: sorrentotherapeutics.com

    Peers

    $CLDX
    $FATE

    Recent Analyst Ratings for Sorrento Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    11/2/2022$5.00Overweight
    Cantor Fitzgerald
    8/9/2021$30.00 → $26.00Buy
    HC Wainwright & Co.
    See more ratings

    Sorrento Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Sorrento Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Sorrento Therapeutics with a rating of Overweight and set a new price target of $5.00

      11/2/22 6:29:52 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sorrento Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00 from $30.00 previously

      8/9/21 6:25:18 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • B. Riley Securities initiated coverage on Sorrento Therapeutics with a new price target

      B. Riley Securities initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00

      1/29/21 7:40:31 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Alliance Global Partners initiated coverage on Sorrento Therapeutics

      Alliance Global Partners initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $35

      1/21/21 10:28:55 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Alliance Global Partners initiated coverage on Sorrento Therapeutics

      Alliance Global Partners initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $35

      1/21/21 10:28:55 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Sorrento Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sorrento Therapeutics Inc. (Amendment)

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      3/10/23 11:21:36 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Sorrento Therapeutics Inc.

      SC 13G - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/17/23 4:07:18 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Sorrento Therapeutics Inc. (Amendment)

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/9/23 3:48:42 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Sorrento Therapeutics Inc.

      SC 13G - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      7/11/22 11:38:40 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/1/21 4:35:34 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/1/21 4:34:47 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/1/21 4:34:20 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/1/21 4:33:57 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/1/21 4:33:26 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/1/21 4:32:51 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Sorrento Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

      US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

      1/31/25 9:00:00 AM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Posts Form 8937 to Supplement its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")

      SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company ("Scilex") previously held by Sorrento. The Form 8937 has been filed with the Internal Revenue Service and Sorrento expects to send copies of the form in the coming days to brokerage firms, banks, dealers and similar organizations to whom a dividend confirmation had previously been distr

      2/18/23 8:37:04 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Issues Update to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")

      SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an update to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the "Dividend Stock"). The update to the FAQs provides notice regarding the no lien code added on Scilex (NASDAQ:SCLX) common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a

      2/17/23 3:47:31 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Issues Supplement to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock

      SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed

      2/2/23 2:12:00 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock

      PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and

      2/2/23 1:15:35 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™

      COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant.COVISTIX has an enhanced sensitivity in detecting the Omicron variant with a more than 10-fold lower limit of detection (LoD) as compared to that of the original SAR-CoV-2 strain.COVISTIX has been approved for emergency use and is on the market in Brazil and Mexico, and is CE marked for sale in Europe for professional point-of-care use.In response to increasing product demand, Sorrento has invested and becomes a majority owner with an option to acquire 100% of FortuneBio, a diagnostic product manufacturer with dozens of approved diagnostic pro

      2/17/22 1:02:49 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis

      Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable at-home diagnostic platform ("Virex Technology").Virex Technology, invented and developed by Boston University (BU) Professors Mark Grinstaff and Scott Schaus and Virex scientists, employs widely used electrochemistry found in household diabetes glucometer devices for next generation diagnostics.Virex Technology has demonstrated extremely high sensitivity for multiple biological analytes including COVID-19 virus detection as sensitive as 10 TCID50, rivalling PCR sensitivity.Virex's early liver cancer biomarker test detects a liver cancer biomarker in as little as 2 microliters of blood.Vir

      2/1/22 9:00:00 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

      Executed binding term sheet with Sorrento Therapeutics (NASDAQ:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidateNew collaboration with India's Syngene International to develop a COVID-19 vaccine candidateNew co-development collaboration with South Africa's Rubic consortium to establish a basis for researching, developing, and manufacturing multiple other C1 produced vaccines in addition to DYAI-100Potential to support vaccine production for up to 100% of the world's populationDyadic's C1 productio

      8/12/21 4:00:00 PM ET
      $DYAI
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise

      AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL CELL LUNG CANCER (NSCLC) AND B-CELL LYMPHOMA: Abivertinib is potentially one of the most effective clinical-stage dual tyrosine kinase inhibitors (TKI), targeting both mutant epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).Abivertinib is a pyrrolopyrimidine-based irreversible third-generation (3G) EGFR TKI, structurally distinct from all other 3G pyrimidine-based EGFR inhibitors.More than 600 cancer patients have been treated with Abivertinib with a strong safety profi

      6/2/21 9:00:00 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Sorrento Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

      PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

      7/5/22 2:04:42 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji

      SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento's Chairman and CEO Henry Ji. Governor Thompson's appointment is effective immediately. Most recently, Thompson served as the President of the University of Wisconsin System from July 2020 through March 2022, one of the largest

      6/24/22 3:38:28 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

      SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche Laboratories executive, Tammy Reilly, to Sorrento's board of directors. Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer merchandising and healthcare diagnostic companies to Sorrento.  "Sorrento continues to strengthen its already experienced board of directors," said Henry Ji, Ph.D., Chairman and Chief Executive O

      5/18/22 9:00:00 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Scilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)

      SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022. Ms. Czerepak will be a member of the Scilex and Sorrento Executive Leadership Teams, reporting to Scilex's Chief Executive Officer and President, Jaisim Shah, and Sorr

      4/28/22 9:00:00 AM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

      PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to

      4/12/22 9:15:46 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Better For You Wellness Appoints Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD to its Board of Directors

      Columbus, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that it has appointed five independent non-executive directors to its Board of Directors including Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD (the "New Directors"). All five New Directors have been appointed for initial terms of 2 years, and Better For You Wellness, Inc.'s seven member Board of Directors is now composed of a majority of Independent Directors demonstrating the Company's focus on governance

      9/2/21 9:29:00 AM ET
      $HSDT
      $SRNE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    Sorrento Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

      US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

      1/31/25 9:00:00 AM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

      SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023.  The financing will provide Sorrento with immediate liquidity so that it can continue operating its business as usual during its chapter 11 case. A hearing for final approval of

      2/21/23 5:57:00 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Posts Form 8937 to Supplement its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")

      SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company ("Scilex") previously held by Sorrento. The Form 8937 has been filed with the Internal Revenue Service and Sorrento expects to send copies of the form in the coming days to brokerage firms, banks, dealers and similar organizations to whom a dividend confirmation had previously been distr

      2/18/23 8:37:04 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Issues Update to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")

      SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an update to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the "Dividend Stock"). The update to the FAQs provides notice regarding the no lien code added on Scilex (NASDAQ:SCLX) common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a

      2/17/23 3:47:31 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions

      SAN DIEGO, Feb. 16, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento's employee wages motion and interim approval of its cash management motion, in connection with Sorrento's chapter 11 petition, which was filed on February 13, 2023.  Sorrento expects to seek approval of other customary "first day" motions in the coming days.

      2/16/23 2:41:00 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today's Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

      SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements: Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento, commented: "Today, Sorrento Therapeutics, Inc. and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. ("Scintilla"), commenced voluntary proceedings under Chapter 11 of

      2/13/23 3:46:44 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

      PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that its first virtual-only Annual Meeting of Stockholders (the "Meeting") is scheduled to be held on April 6, 2023 at 9AM PST. Scilex also announced that its Board of Directors has set the close of business on March 6, 2023 as the record date (the "Record Date") for determining stockholders entitled to notice of, and to

      2/4/23 10:48:18 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock

      SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))) held by Sorrento. These statements, which contain the account numbers and amount of Scilex dividend shares, were previously mailed out by Continental Stock Transfer & Trust Company. The dividend confirmation statements are being distributed on behalf of Sorrento and Scilex to notify each brokerage firm of Sorrento's previously announced stock dividend (the "Dividend") consisting of an a

      2/3/23 8:59:53 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Issues Supplement to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock

      SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed

      2/2/23 2:12:00 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock

      PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and

      2/2/23 1:15:35 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    Sorrento Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sorrento Therapeutics Inc.

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      3/20/23 7:52:53 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 5: Janda Kim closing all direct ownership in the company

      5 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      2/6/23 9:10:05 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry exercised 500 in-the-money shares at a strike of $5.50

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      12/23/22 2:28:10 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry was granted 1,500,000 shares, increasing direct ownership by 31% to 6,265,805 units

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      12/16/22 8:10:21 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry bought $179,349 worth of shares (88,888 units at $2.02), increasing direct ownership by 2% to 4,765,805 units

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      9/7/22 6:22:33 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry bought $108,882 worth of shares (55,555 units at $1.96), increasing direct ownership by 1% to 4,676,917 units

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      9/6/22 5:24:30 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry was granted 2,500,000 shares, increasing direct ownership by 118% to 4,621,362 units

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      9/2/22 4:31:50 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry bought $70,333 worth of shares (33,333 units at $2.11), increasing direct ownership by 2% to 2,121,362 units

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      8/26/22 5:33:42 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry bought $45,768 worth of shares (22,222 units at $2.06), increasing direct ownership by 1% to 2,088,029 units

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      8/25/22 5:18:13 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry bought $13,999 worth of shares (10,000 units at $1.40), increasing direct ownership by 0.49% to 2,065,807 units

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      6/14/22 5:15:20 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    Sorrento Therapeutics Inc. SEC Filings

    See more
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      11/7/23 4:34:31 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      11/3/23 5:31:06 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      10/5/23 5:26:12 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Regulation FD Disclosure, Other Events

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      9/26/23 4:54:59 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      9/12/23 9:51:06 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      8/28/23 5:25:07 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      8/21/23 11:20:18 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by Sorrento Therapeutics Inc.

      10-Q - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      8/11/23 8:00:12 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      8/10/23 4:14:19 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form NT 10-Q filed by Sorrento Therapeutics Inc.

      NT 10-Q - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      8/7/23 4:15:35 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care